Company Analysis
Sign in

Ultragenyx Pharmaceutical Inc. (RARE)

Nasdaq: RARE · Pharmaceutical Preparations · Novato, CA · filing with the SEC since 2011
Full chart Alerts Compare
Grade5.9
◀ Past 7.5● Present 5.9▶ Future 4.5
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

28 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Ultragenyx Pharmaceutical Inc.’s names, not what it holds today.

Patents granted
28
28 utility, 1976 to Dec 31, 2025
Granted in 2025
4
Against 3 in 2024 and 3 in 2023
Applications published
67
10 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Biotechnology7
Pharmaceuticals5
Organic fine chemistry3
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Ultragenyx Pharmaceutical Inc. its own name
named as the applicant on its applications, in US. 1 more under the same name are not counted (printed in CA)
0 granted
56 published
Ultragenyx Pharmaceutical Inc. its own name
US, as the owner printed on each patent
28 granted
11 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 2, 202512,487,152Scalable method for producing transfection reagentsBiotechnologyUltragenyx Pharmaceutical Inc.
Nov 18, 202512,472,268Gene therapy for treating propionic acidemiaBiotechnologyUltragenyx Pharmaceutical Inc.
Jul 15, 202512,358,976Methods for increasing serum concentration of phosphorous and/or 1,25-hydroxy vitamin dPharmaceuticalsUltragenyx Pharmaceutical Inc.
Jun 24, 202512,338,450Gene therapy constructs for treating Wilson diseasePharmaceuticalsUltragenyx Pharmaceutical Inc.
Jun 25, 202412,018,288Engineered producer cell lines and methods of making and using the sameBiotechnologyUltragenyx Pharmaceutical Inc.
Apr 2, 202411,944,658Methods of heat inactivation of adenovirusBiotechnologyUltragenyx Pharmaceutical Inc.
Feb 13, 202411,898,170Cell culture methods involving HDAC inhibitors or rep proteinsBiotechnologyUltragenyx Pharmaceutical Inc.
Oct 24, 202311,795,473Use of tonicifying agents to enhance recombinant adeno-associated virus yieldBiotechnologyUltragenyx Pharmaceutical Inc.
Oct 3, 202311,771,748Methods for treating tumor-induced osteomalaciaPharmaceuticalsUltragenyx Pharmaceutical Inc.
Sep 12, 202311,753,369Creatine prodrugs, compositions and methods of use thereofOrganic fine chemistryUltragenyx Pharmaceutical Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Oct 30, 20252025/0333763GENE THERAPY CONSTRUCTS FOR TREATING WILSON DISEASEPharmaceuticalsUltragenyx Pharmaceutical Inc.
Sep 25, 20252025/0297251CERTAIN DUX4 INHIBITORS AND METHODS OF USE THEREOFPharmaceuticalsUltragenyx Pharmaceutical Inc.
Aug 14, 20252025/0255828LYOPHILIZED LIPID NANOPARTICLES AND METHODS OF THEIR USEPharmaceuticalsUltragenyx Pharmaceutical Inc.
Jul 17, 20252025/0230418MODIFIED BATCH AAV PRODUCTION SYSTEMS AND METHODSBiotechnologyUltragenyx Pharmaceutical Inc.
Apr 17, 20252025/0120936COMPOSITIONS OF TRIGLYCERIDES AND USES THEREOFPharmaceuticalsUltragenyx Pharmaceutical Inc.
Apr 17, 20252025/0120935COMPOSITIONS OF TRIGLYCERIDES AND USES THEREOFPharmaceuticalsUltragenyx Pharmaceutical Inc.
Jan 16, 20252025/0019721COMPOSITIONS AND METHODS FOR TREATING A MUSCULAR DYSTROPHYBiotechnologyUltragenyx Pharmaceutical Inc.
Jan 16, 20252025/0019668ENGINEERED CELL LINES FOR INCREASED PRODUCTION OF RECOMBINANT ADENO-ASSOCIATED VIRUS (RAAV)BiotechnologyUltragenyx Pharmaceutical Inc.
Jan 9, 20252025/0011810RECOMBINANT AAV FORMULATIONSPharmaceuticalsUltragenyx Pharmaceutical Inc.
Jan 9, 20252025/0011407METHODS OF USING ANTI-SCLEROSTIN ANTIBODIES IN TREATMENT OF OSTEOGENESIS IMPERFECTAPharmaceuticalsUltragenyx Pharmaceutical Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 9 · Biotechnology 5 · Organic fine chemistry 1 · Chemical engineering 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton RARE · research, not advice